戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osynthesis inhibitor) and chloramphenicol (a protein synthesis inhibitor).
2  protein kinase II (CaMKII) inhibitors and a protein synthesis inhibitor.
3  triggers p100 processing in the presence of protein synthesis inhibitor.
4  is blocked by the presence of anisomycin, a protein synthesis inhibitor.
5 N varicosities were blocked by anisomycin, a protein synthesis inhibitor.
6 rin gene expression, even in the presence of protein synthesis inhibitor.
7  by measuring the coentry of alpha-sarcin, a protein synthesis inhibitor.
8 nfections are performed in the presence of a protein synthesis inhibitor.
9    Here, we demonstrate that mefloquine is a protein synthesis inhibitor.
10 erm treatment with lincomycin, a chloroplast protein synthesis inhibitor.
11 h, which was unaffected by pretreatment with protein synthesis inhibitor.
12 s venezuelae, represent minimalist macrolide protein synthesis inhibitors.
13 ith cell wall active antibiotics rather than protein synthesis inhibitors.
14 we explored the effect of several eukaryotic protein synthesis inhibitors.
15 polymerization were completely suppressed by protein synthesis inhibitors.
16 epatocytes within 24 hours in the absence of protein synthesis inhibitors.
17 ive-strand RNAs in the presence of different protein synthesis inhibitors.
18  sensitive than wild-type strains to certain protein synthesis inhibitors.
19  LTD has a late phase that may be blocked by protein synthesis inhibitors.
20 antly affect ongoing P-LTF in the absence of protein synthesis inhibitors.
21 EC) produces Shiga-like toxins (SLT), potent protein synthesis inhibitors.
22  nocodazole-treated cells in the presence of protein synthesis inhibitors.
23 comprise an important class of antibacterial protein synthesis inhibitors.
24 rowth factor pathway by its insensitivity to protein synthesis inhibitors.
25 pressing P-LTF in the absence or presence of protein synthesis inhibitors.
26 mpounds, including 5a and 5k, seem to act as protein synthesis inhibitors.
27 s can be directly modulated by commonly used protein synthesis inhibitors.
28 me serotypes of Escherichia coli, are potent protein synthesis inhibitors.
29 d when hippocampal neurons were treated with protein synthesis inhibitors.
30 glucocorticoids, microtubule inhibitors, and protein synthesis inhibitors.
31 esia vary substantially after treatment with protein synthesis inhibitors.
32 xamined this hypothesis by local infusion of protein-synthesis inhibitor after devaluation of a food
33               Genomic modulators including a protein synthesis inhibitor, an RNA synthesis inhibitor,
34    This effect occurred in the presence of a protein synthesis inhibitor and also in the absence of m
35 ein kinase inhibitor staurosporine, with the protein synthesis inhibitor and protein kinase activator
36                              Stxs are potent protein synthesis inhibitors and are the primary virulen
37 AR1 or LTV1 are hypersensitive to particular protein synthesis inhibitors and exhibit aberrant polyso
38 hepatocyte cultures using a broader array of protein synthesis inhibitors and experimental end points
39 g sensitivities to low temperatures, certain protein synthesis inhibitors and high osmolarity.
40 transcription factors, apoptosis regulators, protein synthesis inhibitors and protein degradation fac
41 of transcription, homoharringtonine (HHT), a protein synthesis inhibitor, and imatinib were used sing
42  We found that both cycloheximide, a general protein synthesis inhibitor, and rapamycin, a selective
43 nd GABAB receptors, occur in the presence of protein synthesis inhibitors, and are not influenced by
44  stimuli such as heat shock, UV irradiation, protein synthesis inhibitors, and conditions that elevat
45 his factor, that persists in the presence of protein synthesis inhibitors, and that is therefore medi
46 h a specific context, and the ability of the protein synthesis inhibitor anisomycin administered foll
47  Biedenkapp and J. W. Rudy reported that the protein synthesis inhibitor anisomycin administered into
48 c or intra-hippocampal administration of the protein synthesis inhibitor anisomycin generally leads t
49 at the impairments in behavior caused by the protein synthesis inhibitor anisomycin given after retri
50                          The presence of the protein synthesis inhibitor anisomycin had no effect on
51 mpus 48 h after contextual training with the protein synthesis inhibitor anisomycin impaired memory p
52                              Infusion of the protein synthesis inhibitor anisomycin into the LBA shor
53                                          The protein synthesis inhibitor anisomycin was administered
54 ependent LTD in AS mice was sensitive to the protein synthesis inhibitor anisomycin, and relied on th
55 ion training, followed by treatment with the protein synthesis inhibitor anisomycin, LTS was disrupte
56 ppocampal infusions of vehicle (VEH), of the protein synthesis inhibitor anisomycin, of the D1/D5 dop
57           Both responses were blocked by the protein synthesis inhibitor anisomycin.
58 nosylbenzimidazole (DRB), or infusion of the protein synthesis inhibitor anisomycin.
59  of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomycin.
60 gen peroxide, menadione, heat shock, and the protein synthesis inhibitor anisomycin.
61 e inhibited period was also inhibited by the protein synthesis inhibitor anisomycin.
62                             In contrast, the protein synthesis inhibitors anisomycin and puromycin di
63 s effect is antagonized by administration of protein synthesis inhibitors anisomycin and rapamycin in
64 h were prevented by local application of the protein synthesis inhibitors anisomycin or rapamycin.
65 + MPEP) and their induction was prevented by protein synthesis inhibitor (anisomycin).
66 a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximid
67                     Animals treated with the protein synthesis inhibitor, anisomycin, into either the
68                             Infusions of the protein synthesis inhibitor, anisomycin, prior to defeat
69 eam cellular activation was prevented when a protein synthesis inhibitor, anisomycin, was administere
70 ion, which was inhibited by intrahippocampal protein synthesis inhibitor anisomysin, D1/D5 dopaminerd
71                                              Protein synthesis inhibitor antibiotics are widely used
72 lts suggest that (1) the amnestic effects of protein synthesis inhibitors are confounded by neural si
73 signaling is delayed and can be inhibited by protein synthesis inhibitor as well as why most classica
74 the data identify microtubule inhibitors and protein synthesis inhibitors as modulators of PGC-1alpha
75 actinomycin D (Act D, 20 micromol/L; n=6), a protein synthesis inhibitor at the transcriptional level
76 d with cycloheximide (CHx, 10 micromol/L), a protein synthesis inhibitor at the translational level,
77                                              Protein synthesis inhibitors block mossy fiber(MF) LTP m
78                                              Protein synthesis inhibitors block the maintenance of NM
79 RNA synthesis inhibitor) or cycloheximide (a protein synthesis inhibitor) blocked ganglionic movement
80               Bath application of emetine, a protein synthesis inhibitor, blocked eCB-LTD after affer
81 hrine-deprived conditions in the presence of protein synthesis inhibitor, both the IP3 response and t
82  not only be a function of hygromycin B as a protein synthesis inhibitor but also possibly related to
83    Restoration occurred in the presence of a protein synthesis inhibitor but not after a transcriptio
84 lic inhibitors revealed that cycloheximide a protein synthesis inhibitor, but not phosphonoacetic aci
85 mulation was insensitive to cycloheximide, a protein synthesis inhibitor, but was completely inhibite
86 lease was not diminished by transcription or protein synthesis inhibitors, but was suppressed by bref
87        A brief treatment of the cells with a protein synthesis inhibitor can abolish okadaic acid-ind
88 owever, old memories that are insensitive to protein synthesis inhibitors can become vulnerable if th
89 d by the production of new proteins, because protein synthesis inhibitors can block retrieval of rece
90 e resulting compendium revealed, first, that protein synthesis inhibitors can decouple coordination o
91 nse was cycloheximide-sensitive, because the protein synthesis inhibitor caused a GC-dependent superi
92 lls expressing the transfected TRH receptor, protein synthesis inhibitors caused translocation of int
93          Treatment of E. coli cells with the protein synthesis inhibitor chloramphenicol abolished re
94                                          The protein synthesis inhibitor chloramphenicol prevents the
95 ell-wall-active antibiotic ampicillin or the protein synthesis inhibitor clindamycin or azithromycin.
96                We found that addition of the protein synthesis inhibitor clindamycin to S. aureus LAC
97  occurs in cells that have been treated with protein synthesis inhibitors, consistent with a displace
98                Here, we report that specific protein synthesis inhibitors could either significantly
99 anscription inhibitor actinomycin D, and the protein synthesis inhibitor cyclohexamide suggest that M
100                               The eukaryotic protein synthesis inhibitor cycloheximid has been used b
101 bitor actinomycin-D (0.5 microg ml(-1)), the protein synthesis inhibitor cycloheximide (1 microg ml(-
102 e GR antagonist RU-486 (1-10 microM), or the protein synthesis inhibitor cycloheximide (1 microM) fai
103 ect, HCjE cells were treated with RA and the protein synthesis inhibitor cycloheximide (1.0 microg/mL
104 llowing harmful ischemia were blocked by the protein synthesis inhibitor cycloheximide (1.0 muM), a k
105 he generation of IL-8 during chemotaxis, the protein synthesis inhibitor cycloheximide (10 microg/ml)
106                                          The protein synthesis inhibitor cycloheximide (10 microg/ml)
107 ycin was verified using a single dose of the protein synthesis inhibitor cycloheximide (40 nmol).
108 nt cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the
109 ment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms
110                           The ability of the protein synthesis inhibitor cycloheximide (CHX) to preve
111 fects of PAF antagonist BN50730 (10 microM), protein synthesis inhibitor cycloheximide (CHX; 30 micro
112 thesis, the authors gave spinalized rats the protein synthesis inhibitor Cycloheximide (CXM) or salin
113               Treatment of TM cells with the protein synthesis inhibitor cycloheximide abolished the
114                        Administration of the protein synthesis inhibitor cycloheximide after training
115                                          The protein synthesis inhibitor cycloheximide also has a cyt
116 is protective effect could be blocked by the protein synthesis inhibitor cycloheximide and by a varie
117                                     Both the protein synthesis inhibitor cycloheximide and cyclin E a
118                                          The protein synthesis inhibitor cycloheximide and the protea
119 y ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appea
120 f HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcript
121  induced by 1S,3R-ACPD was attenuated by the protein synthesis inhibitor cycloheximide as well as by
122 te early gene, pretreatment of mice with the protein synthesis inhibitor cycloheximide before either
123 NA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide both completel
124 thesis of this transcript was blocked by the protein synthesis inhibitor cycloheximide but not by the
125 stigated whether induction of c-Myc by OA or protein synthesis inhibitor cycloheximide contributed to
126                                          The protein synthesis inhibitor cycloheximide decreased GnRH
127                               The eukaryotic protein synthesis inhibitor cycloheximide did not block
128                                  Whereas the protein synthesis inhibitor cycloheximide did not block
129                                          The protein synthesis inhibitor cycloheximide did not block
130                                  Because the protein synthesis inhibitor cycloheximide did not preven
131 n of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-
132 onfluent OCCM cells were pretreated with the protein synthesis inhibitor cycloheximide followed by fl
133 must be maintained by recycling, because the protein synthesis inhibitor cycloheximide has no effect
134        Slowing the translation rate with the protein synthesis inhibitor cycloheximide increased the
135 bitors SB202190 and SB203580 and the general protein synthesis inhibitor cycloheximide inhibited both
136 ylation and that treatment of cells with the protein synthesis inhibitor cycloheximide led to an almo
137                                          The protein synthesis inhibitor cycloheximide markedly (P<.0
138 increase in CCL20 levels was not affected by protein synthesis inhibitor cycloheximide nor protein tr
139 r in vivo intravitreal administration of the protein synthesis inhibitor cycloheximide or lactacystin
140                           Treatment with the protein synthesis inhibitor cycloheximide or RNA interfe
141 is increased by co-treatment with either the protein synthesis inhibitor cycloheximide or the phospha
142                                          The protein synthesis inhibitor cycloheximide potentiated EM
143                 Pretreating the animals with protein synthesis inhibitor cycloheximide prevented I/R-
144 in thyroid cells, whereas treatment with the protein synthesis inhibitor cycloheximide prior to Fas a
145               Experiments performed with the protein synthesis inhibitor cycloheximide provided evide
146                    Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TR
147                                          The protein synthesis inhibitor cycloheximide significantly
148 ections of mGluR1 antagonist JNJ16259685 and protein synthesis inhibitor cycloheximide significantly
149 eins after UV exposure or treatment with the protein synthesis inhibitor cycloheximide were similar.
150 cular and intrahippocampal injections of the protein synthesis inhibitor cycloheximide, administered
151 e cultured in the presence or absence of the protein synthesis inhibitor cycloheximide, and prorenin
152 cluding the immunosuppressant rapamycin, the protein synthesis inhibitor cycloheximide, and several p
153 SA was potent, rapid, and insensitive to the protein synthesis inhibitor cycloheximide, and we conclu
154 ightfold within 6 h after treatment with the protein synthesis inhibitor cycloheximide, but simultane
155 is when administered in combination with the protein synthesis inhibitor cycloheximide, but the apopt
156 atory O2 uptake by SA was insensitive to the protein synthesis inhibitor cycloheximide, but was subst
157 gulate CXCR4 expression was abrogated by the protein synthesis inhibitor cycloheximide, clearly indic
158 oproteins by responders was resistant to the protein synthesis inhibitor cycloheximide, coincided wit
159 FQR1 mRNA abundance is not diminished by the protein synthesis inhibitor cycloheximide, demonstrating
160 ol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating th
161                       In the presence of the protein synthesis inhibitor cycloheximide, LPS primarily
162      Sensitivity of the MDR RV+ cells to the protein synthesis inhibitor cycloheximide, saponin, and
163                   In the presence of de novo protein synthesis inhibitor cycloheximide, SGN-40 signif
164 DR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that
165 nscription is induced in the presence of the protein synthesis inhibitor cycloheximide, so it appears
166 d apoptosis did occur in the presence of the protein synthesis inhibitor cycloheximide, suggesting th
167 affected keratinocytes were treated with the protein synthesis inhibitor cycloheximide, the steady-st
168                                    Using the protein synthesis inhibitor cycloheximide, we investigat
169 ver of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overe
170                                 Finally, the protein synthesis inhibitor cycloheximide, which complet
171 ent fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, while Ski is
172 y H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide.
173 tein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.
174 is ineffective unless in the presence of the protein synthesis inhibitor cycloheximide.
175 n by "superinduction" in the presence of the protein synthesis inhibitor cycloheximide.
176 a reappearance was completely blocked by the protein synthesis inhibitor cycloheximide.
177 c bcl-2 family member bax or addition of the protein synthesis inhibitor cycloheximide.
178 aspartate receptor antagonist MK-801 and the protein synthesis inhibitor cycloheximide.
179 coid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.
180 n band, effects that were insensitive to the protein synthesis inhibitor cycloheximide.
181 -alpha in the same cells pretreated with the protein synthesis inhibitor cycloheximide.
182 ent with the antiestrogen ICI 182,780 or the protein synthesis inhibitor cycloheximide.
183  serial FACS analyses in the presence of the protein synthesis inhibitor cycloheximide.
184 nt in the absence but not in the presence of protein synthesis inhibitor cycloheximide.
185  TNF-alpha expression in the presence of the protein synthesis inhibitor cycloheximide.
186                                    Using the protein synthesis inhibitors cycloheximide and anisomyci
187        Here, we show that the application of protein synthesis inhibitors cycloheximide and emetine t
188 ment for at least 12 h and is blocked by the protein synthesis inhibitors cycloheximide and puromycin
189                                          The protein synthesis inhibitors cycloheximide and puromycin
190                                          The protein synthesis inhibitors cycloheximide and puromycin
191  incorporation was blocked completely by the protein synthesis inhibitors cycloheximide and puromycin
192          On the contrary, treatment with the protein synthesis inhibitors cycloheximide, anisomycin,
193 ynthesis as shown by cell treatment with the protein-synthesis inhibitor cycloheximide.
194 induced by TNF- alpha in the presence of the protein-synthesis inhibitor cycloheximide.
195          Exploration of the effects of other protein synthesis inhibitors (cycloheximide, anisomycin)
196                        Pretreatment with the protein synthesis inhibitor, cycloheximide (CHX, 100 mic
197             Prior treatment of rats with the protein synthesis inhibitor, cycloheximide, also blunted
198                           Interestingly, the protein synthesis inhibitor, cycloheximide, and protein
199 ective effect was abolished by injecting the protein synthesis inhibitor, cycloheximide, and the affe
200                                          The protein synthesis inhibitor, cycloheximide, blocked the
201 hronic administration of anti-rat p75 or the protein synthesis inhibitor, cycloheximide, but not anti
202 obility shift of p66shc was inhibited by the protein synthesis inhibitor, cycloheximide, but not by t
203                               The eukaryotic protein synthesis inhibitor, cycloheximide, caused a >50
204 nd the Notch pathway, or by treatment with a protein synthesis inhibitor, cycloheximide, leads to the
205 ed to apoptosis either by cotreatment with a protein synthesis inhibitor, cycloheximide, or Smac mime
206 s new protein synthesis, as treatment with a protein synthesis inhibitor, cycloheximide, partially re
207                         In the presence of a protein synthesis inhibitor, cycloheximide, tumor necros
208  synthesis inhibitor, actinomycin-D, and the protein synthesis inhibitor, cycloheximide, were examine
209  in response to mechanical agitation and the protein synthesis inhibitor, cycloheximide.
210 ase in Ivr2 transcripts was sensitive to the protein synthesis inhibitor, cycloheximide.
211 rown in low concentrations of the eukaryotic protein synthesis inhibitor, cycloheximide.
212 eath in DIV 7-8 neurons was prevented by the protein-synthesis inhibitor, cycloheximide.
213 478, and re-expression was prohibited by the protein synthesis inhibitor cylcoheximide; the lysosome
214                                              Protein synthesis inhibitors did not prevent Theta Bust
215 e prolonged 1-Hz stimulus in the presence of protein synthesis inhibitors each can be transformed int
216          Additionally, pretreatment with the protein synthesis inhibitor emetine (1 microM) totally p
217                      Bath application of the protein synthesis inhibitor emetine or cycloheximide 1 h
218 amtide-2-related inhibitory peptide, and the protein synthesis inhibitors emetine and anisomycin.
219  influx (diazoxide or nimodipine), whereas a protein synthesis inhibitor (emetine) decreased it by on
220 otonin receptor antagonist (methysergide) or protein synthesis inhibitors (emetine or cycloheximide)
221 on develops slowly and may be treatable with protein synthesis inhibitors, even when treatment is del
222 imals that were injected previously with the protein synthesis inhibitor exhibited significantly less
223 al prevented the memory-impairing effects of protein synthesis inhibitors following retrieval.
224 lipid moieties in the presence or absence of protein synthesis inhibitors had no effect on epithelial
225 tent with this idea was the finding that the protein synthesis inhibitors had no measurable effect on
226 ffects that cell-wall active antibiotics and protein-synthesis inhibitors have on transcription and t
227     RA's effect was blocked by either RNA or protein synthesis inhibitors; however, hCAR mRNA's stabi
228 ctrotransformation before selection with the protein synthesis inhibitor hygromycin B was imposed.
229 ection is sensitive to transcription but not protein synthesis inhibitors, implicating a pretranslati
230 ere we show that anisomycin, a commonly used protein synthesis inhibitor in memory research, impairs
231                          Thus, the effect of protein synthesis inhibitors in stabilizing the GPI-PLC
232 cells, and the effect of transcriptional and protein synthesis inhibitors indicates de novo IL-10 pro
233 till initiates when embryos are treated with protein synthesis inhibitors, indicating that it is medi
234 STM for FC can occur even in the presence of protein synthesis inhibitors, indicating that redistribu
235 properties are lacking in engram cells under protein synthesis inhibitor-induced amnesia, direct opto
236    In addition, cycloheximide (10 microM), a protein synthesis inhibitor, inhibited the effect of str
237            This OM effect was not blocked by protein synthesis inhibitors, inhibitors of p38 kinase,
238 yos or embryos arrested in interphase with a protein synthesis inhibitor, injection of CycB accelerat
239                      Finally, injection of a protein synthesis inhibitor into either ilPFC or CeA imp
240 s preceded by bilateral microinjections of a protein synthesis inhibitor into the basolateral amygdal
241                    Postsession infusion of a protein synthesis inhibitor into the prelimbic cortex di
242                       Although injecting the protein-synthesis inhibitor into the dorsal hippocampus
243 trast, bilateral injections of anisomycin, a protein synthesis inhibitor, into BLA did not impair the
244 f rats received 0.4 mg/kg cycloheximide, the protein synthesis inhibitor, intraperitoneally before pr
245 ar osmotic shock and certain phosphatase and protein synthesis inhibitors, leads to phosphorylation o
246  method, we use drug combinations comprising protein synthesis inhibitors (macrolides, aminoglycoside
247                                     However, protein synthesis inhibitors may have additional detrime
248 ed by nifedipine was not prevented by RNA or protein synthesis inhibitors, nor by the caspase inhibit
249 tro, but little is known about the effect of protein synthesis inhibitors on either induction or main
250               Furthermore, incubation with a protein synthesis inhibitor or an NMDAR-antagonist impai
251 ked by tyrosine kinase inhibition but not by protein synthesis inhibitors or cytochalasin D.
252                               Treatment with protein synthesis inhibitors or the expression of the do
253       The DNA degradation was insensitive to protein synthesis inhibitors or UV inactivation of virus
254                                  Anisomycin (protein synthesis inhibitor) or KT5720 (protein kinase A
255 ately by intra-LA infusions of anisomycin (a protein synthesis inhibitor) or Rp-cAMPS (an inhibitor o
256  session, either a solution of anisomycin (a protein synthesis inhibitor) or vehicle was bilaterally
257 ed Sar1p mutant protein in the presence of a protein synthesis inhibitor, or by plasmid-encoded expre
258  cells, the addition of either anisomycin, a protein synthesis inhibitor, or geranylgeraniol, an inte
259                                         With protein synthesis inhibitors, phrenic LTF differed from
260 tibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial acti
261 -such that when presented in the presence of protein synthesis inhibitors produce a rapid reversal of
262 cium chelation and by preincubation with the protein synthesis inhibitor puromycin.
263                          Incubation with the protein synthesis inhibitor rapamycin during the second
264 tivation was followed by incubation with the protein synthesis inhibitor rapamycin.
265                                  Infusion of protein synthesis inhibitors (rapamycin or anisomycin) i
266 ent of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to
267 ing culture of VZ cells in the presence of a protein synthesis inhibitor results after 20 h in a loss
268 cell line by treatment with cycloheximide, a protein synthesis inhibitor, showing that the level of A
269      Here we show that YoeB, a highly potent protein synthesis inhibitor, specifically blocks transla
270  further experiments demonstrated that these protein synthesis inhibitors stimulated rapid and differ
271                                 Finally, the protein synthesis inhibitors Stx1 and anisomycin trigger
272                          Amnesia produced by protein synthesis inhibitors such as anisomycin provides
273    This view stems from the observation that protein synthesis inhibitors, such as anisomycin (ANI),
274 but does not affect sensitivity toward other protein synthesis inhibitors, such as saporin or cyclohe
275                                   The use of protein synthesis inhibitors suggested that newly synthe
276 al inhibitor) as well as by cycloheximide (a protein synthesis inhibitor), suggesting the involvement
277 anscriptional levels and was unaffected by a protein synthesis inhibitor, suggesting that this did no
278 e transcriptional level and was sensitive to protein synthesis inhibitors, suggesting a requirement f
279 ion in Fragile X mutants could be rescued by protein synthesis inhibitors, suggesting that excess bas
280 en gene expression, whereas cycloheximide, a protein synthesis inhibitor, superinduced the expression
281      Harringtonine, a structurally unrelated protein synthesis inhibitor that competes with trichothe
282               Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activi
283 deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a domi
284     Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneup
285               Streptogramins A is a class of protein synthesis inhibitors that target the peptidyl tr
286 erience and shortly afterward treated with a protein synthesis inhibitor, the consolidated memory for
287                We found that the addition of protein synthesis inhibitors to acute slices (in which s
288  be restored by the selective application of protein synthesis inhibitors to distal axons.
289 strategy in KSHV-infected cells treated with protein synthesis inhibitors to identify direct transcri
290                                  Addition of protein synthesis inhibitors to TRAIL-resistant melanoma
291          Furthermore, our data show that the protein synthesis inhibitors used previously to test the
292 e inclusion by incubation in the presence of protein synthesis inhibitors, vesicles containing elemen
293 f conditioned responses, indicating that the protein synthesis inhibitor was applied to the eyeblink-
294       It was prevented when cycloheximide, a protein synthesis inhibitor, was added up to 6 hr after
295                                        Using protein synthesis inhibitors we showed that the degradat
296                                         When protein synthesis inhibitors were added 15 min before ad
297 indicated that the new macrolides are potent protein synthesis inhibitors, which interact with methyl
298 yed increase in synaptotagmin was blocked by protein synthesis inhibitors, while the early increase i
299  hypotheses that delayed administration of a protein synthesis inhibitor would be effective in reduci
300 ypothesized that the use of a bacteriostatic protein synthesis inhibitor would improve outcomes by re

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top